Hubei Biocause Pharmaceutical Cash Flow Reinvestment Rate
Hubei Biocause Pharmaceutical cash flow reinvestment rate. Hubei Biocause Pharmaceutical (000627) has a Cash Flow Reinvestment Rate of 35.61x as of September 2023, reinvesting CN¥9.83 Billion (capex CN¥10.51 Million plus investments CN¥-9.82 Billion) from operating cash flow of CN¥276.06 Million. Explore how well can Hubei Biocause Pharmaceutical service its debt to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Hubei Biocause Pharmaceutical (2001–2023)
Cash flow reinvestment rate of Hubei Biocause Pharmaceutical from 2001 to 2023. Historical reinvestment intensity for Hubei Biocause Pharmaceutical across 16 annual periods. Explore 000627 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Hubei Biocause Pharmaceutical Cash Flow Reinvestment Rate by Year (2001–2023)
Hubei Biocause Pharmaceutical cash flow reinvestment rate by year from 2001 to 2023. Year-by-year capital reinvestment analysis for Hubei Biocause Pharmaceutical. For the full cash flow conversion analysis, see how efficiently does Hubei Biocause Pharmaceutical generate cash.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 0.39x | CN¥3.71 Billion | CN¥9.53 Billion | CN¥67.53 Million | ▼ -81.4% |
| 2022 | 2.09x | CN¥15.75 Billion | CN¥7.52 Billion | CN¥135.06 Million | ▼ -64.4% |
| 2021 | 5.88x | CN¥24.52 Billion | CN¥4.17 Billion | CN¥287.13 Million | ▲ +854.9% |
| 2020 | 0.62x | CN¥13.18 Billion | CN¥21.42 Billion | CN¥319.51 Million | ▼ -60.7% |
| 2019 | 1.57x | CN¥44.77 Billion | CN¥28.60 Billion | CN¥717.10 Million | ▲ +38.1% |
| 2018 | 1.13x | CN¥16.99 Billion | CN¥14.98 Billion | CN¥274.67 Million | ▼ -97.2% |
| 2017 | 40.64x | CN¥17.54 Billion | CN¥431.58 Million | CN¥778.95 Million | ▲ +3589.5% |
| 2013 | 1.10x | CN¥143.80 Million | CN¥130.53 Million | CN¥143.80 Million | ▼ -19.6% |
| 2012 | 1.37x | CN¥128.50 Million | CN¥93.79 Million | CN¥128.50 Million | ▼ -38.6% |
| 2011 | 2.23x | CN¥149.37 Million | CN¥66.95 Million | CN¥149.37 Million | ▲ +438.3% |
| 2010 | 0.41x | CN¥93.09 Million | CN¥224.58 Million | CN¥93.09 Million | ▼ -24.1% |
| 2007 | 0.55x | CN¥64.76 Million | CN¥118.56 Million | CN¥64.76 Million | ▼ -46.2% |
| 2006 | 1.02x | CN¥130.12 Million | CN¥128.19 Million | CN¥130.12 Million | ▲ +101.5% |
| 2005 | 0.50x | CN¥24.51 Million | CN¥48.66 Million | CN¥24.51 Million | ▲ +10.7% |
| 2004 | 0.46x | CN¥25.52 Million | CN¥56.07 Million | CN¥25.52 Million | ▼ -46.0% |
| 2001 | 0.84x | CN¥31.47 Million | CN¥37.30 Million | CN¥31.47 Million | — |